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Hospitalization rates
from radiotherapy complications
in the United States
Raees Tonse1, Venkataraghavan Ramamoorthy2, Muni Rubens3, Anshul Saxena2,
Peter McGranaghan2, Emir Veledar2, Matthew D. Hall1,4, Michael D. Chuong1,4,
Manmeet S. Ahluwalia4,5, Minesh P. Mehta1,4 & Rupesh Kotecha1,4*
Hospitalizations due to radiotherapy (RT) complications result in significant healthcare expenditures
and adversely affect the quality of life of cancer patients. Using a nationally representative dataset,
the objective of this study is to identify trends in the incidence of these hospitalizations, their causes,
and the resulting financial burden. Data from the National Inpatient Sample was retrospectively
analyzed from 2005 to 2016. RT complications were identified using ICD-9 and ICD-10 external
cause-of-injury codes. The hospitalization rate was the primary endpoint, with cost and in-hospital
death as secondary outcomes. 443,222,223 weighted hospitalizations occurred during the study
period, of which 482,525 (0.11%) were attributed to RT. The 3 most common reasons for RT-related
hospitalization were cystitis (4.8%, standard error [SE] = 0.09), gastroenteritis/colitis (3.7%, SE = 0.07),
and esophagitis (3.5%, SE = 0.07). Aspiration pneumonitis (1.4-fold) and mucositis (1.3-fold) had the
highest relative increases among these hospitalizations from 2005 to 2016, while esophagitis (0.58fold) and disorders of the rectum and anus were the lowest (0.67-fold). The median length of stay of
patient for hospitalization for RT complications was 4.1 (IQR, 2.2–7.5) days and the median charge per
patient was $10,097 (IQR, 5755–18,891) and the total cost during the study period was $4.9 billion.
Hospitalization for RT-related complications is relatively rare, but those that are admitted incur a
substantial cost. Use of advanced RT techniques should be employed whenever possible to mitigate
the risk of severe toxicity and therefore reduce the need to admit patients.
Cancer is one of the most common causes of morbidity and mortality in the United States, with an estimated
1,806,590 new cancer cases1. A substantial proportion of cancer patients with solid tumors undergo radiotherapy at some point during their disease course2, 3. Each year approximately 650,000 individuals in the United
States receive radiotherapy or c hemotherapy4. Although RT offers significant clinical benefit to cancer patients,
either curative or palliative, adverse effects are possible some of which may be severe and ultimately require
hospitalization5, 6. Hospitalizations among cancer patients undergoing RT and chemotherapy have been evaluated and reported in several studies5, 7–11. Majority of these studies report that neutropenia, thrombocytopenia,
anemia and infections to be the leading causes of hospitalization. Jairam et al. evaluated the financial burden of
treatment-related complications of systemic therapy and radiotherapy for patients who were treated in emergency
departments in the United States. However, there was a paucity of data from a nationally representative dataset
that showed the incidence and hospitalizations due to RT complications.
Hospitalization for RT complications entails high costs and is a huge burden on the patients and healthcare
system. According to a MedStat analysis from 2007, each of these hospitalizations cost an average of $22,000 per
patient12. Furthermore, hospitalization causes treatment disruptions and can adversely affect treatment response.
Understanding the nature of these hospitalizations could aid in the development of preventive strategies to in
the outpatient setting. Although similar studies have been performed for chemotherapy-related toxicities and
hospitalizations, to our knowledge a comprehensive analysis of hospitalizations resulting from RT complications
at the national level has not been done. Using a nationally representative dataset, we have aimed to classify the
incidence and causes of these hospitalizations and the financial burden associated with these hospitalizations.
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Tumor type

Number of hospitalizations, n (%)

Solid
Lung

100,392 (20.8%, 95% CI 19.1–21.6%)

Head and neck

58,073 (12.0%, 95% CI 10.8–12.7%)

Rectum and anus

35,134 (7.3%, 95% CI 6.8–8.1%)

Breast

43,345 (9.0%, 95% CI 8.2–9.9%)

Cervix

28,162 (5.8%, 95% CI 4.8–6.7%)

Uterus

17,918 (3.7%, 95% CI 3.1–4.4%)

Colon

17,505 (3.6%, 95% CI 3.2–4.4%)

Bladder

14,951 (3.1%, 95% CI 2.6–3.8%)

Esophagus

13,318 (2.8%, 95% CI 2.1–3.5%)

Other

11,546 (2.4%, 95% CI 1.8–3.2%)

Brain and nervous system

10,922 (2.3%, 95% CI 1.8–3.1%)

Bone and connective tissue

8474 (1.8%, 95% CI 0.9–2.7%)

Prostate

83,771 (17.4%, 95% CI 16.8–18.1%)

Kidney and renal

6391 (1.3%, 95% CI 0.7–2.0%)

Stomach

5704 (1.2%, 95% CI 0.8–1.9%)

Ovary

5357 (1.1%, 95% CI 0.7–1.9%)

Melanoma

5108 (1.1%, 95% CI 0.7–1.8%)

Thyroid

4845 (1.0%, 95% CI 0.6–2.0%)

Pancreas

4506 (0.93%, 95% CI 0.67–1.35%)

Liver and intrahepatic bile duct

2579 (0.53%, 95% CI 0.32–0.98%)

Testis

1375 (0.29%, 95% CI 0.09–0.42%)

Liquid
Non-Hodgkin lymphoma

16,842 (3.5%, 95% CI 3.2–4.4%)

Hodgkin lymphoma

6814 (1.4%, 95% CI 0.7–2.0%)

Leukemia

6698 (1.4%, 95% CI 0.8–1.9%)

Multiple myeloma

3787 (0.78%, 95% CI 0.57–1.2%)

Table 1.  Hospitalizations for complications of radiotherapy by tumor types, 2006–2015.

Methods

Data source. To characterize hospitalizations for RT complications, we analyzed data from the National

Inpatient Sample (NIS) from 2005 to 2016. The NIS was created by the Agency for Healthcare Research and
Quality (AHRQ) as part of the Healthcare Cost and Utilization Project (HCUP) and is the largest all-payer inpatient database in the United S tates13. Researchers and policymakers can utilize NIS to estimate factors including healthcare utilization, hospitalization costs and overall national healthcare costs, all of which are helpful in
making healthcare policy decisions. Every year, the NIS collects data from over 7 million hospitalizations in the
United States. amounting to 35 million weighted hospitalizations. In 2012, the NIS revised its data collection
process in order to obtain a more representative sample of national estimates. Prior to 2012, the NIS gathered
and collected a sample of discharge records from a small number of HCUP hospitals. Aside from demographics,
hospital data, clinical procedures, length of stay, disposition status, and overall costs, each hospitalization datafile comprises one primary and up to 29 secondary diagnoses. Primary and secondary diagnoses were reported
using Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes and Tenth Revision
(ICD-10-CM) codes.

Study design. Cancer patients were identified in the NIS using Classifications Software (CCS) codes
11–4514. Cancers were divided into two categories: solid tumors and hematologic malignancies (see Table 1).
External cause-of-injury codes (E-codes) from ICD-9-CM and ICD-10-CM were used to identify RT complications. The primary reason for hospitalization was the first reported non-cancer disease identified using an ICD9-CM or ICD-10-CM diagnosis code (Supplemental Table 1). The CONSORT diagram depicts the technique for
selecting the patient cohort (Supplemental Fig. 1). The study examined demographics such as age, gender, and
race; socioeconomic factors included median household income by zip code, insurance type; and hospital characteristics included region, bed size, and teaching status. The key end measures were the hospitalization rate and
total cost, while the length of stay in the hospital and in-hospital mortality for RT complications were secondary outcomes. Our findings were reported using the STROBE (Strengthening the Reporting of Observational
Studies in Epidemiology) guidelines. The methods for this study were conducted in accordance with relevant
guidelines and regulations. The study was reviewed by the Miami Cancer Institute’s Institutional Review Board,
which exempted the study from institutional review board approval and waived the requirement for informed
consent because it uses previously collected deidentified data stored in NIS.
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Figure 1.  Percentage of patients admitted for RT related complications by most common cancer types.

Statistical analysis. SAS (version 9.4, SAS Institute, Cary, North Carolina) was used to do statistical analysis. The study followed the guidelines provided by Khera and Krumholz for using NIS d
 ata15. The NIS was
updated in 2012 to be more nationally representative, as previously noted. We used modified discharge weights
for the years 2005–2011 to account for these changes in data c ollection16. Temporal factors, cancer types, demographics, socioeconomic factors, and hospital characteristics were all evaluated using descriptive statistics. Frequencies and percentages were used to describe categorical variables and median and interquartile ranges were
used for continuous variables. The total number of hospitalizations due to RT complications was divided by the
total number of hospitalizations to calculate the hospitalization rates. Total hospital charges and cost-to-charge
ratios were multiplied to calculate the costs of individual inpatient stays. The expenditures for each year were
adjusted based on 2016 inflation levels using the US Consumer Price Index. By subtracting the admission date
from the discharge date, the length of stay in the hospital was calculated. The number of patients admitted for RT
complications who died in the hospital was divided by the total number of patients hospitalized for RT complications to calculate the In-hospital mortality. Weighted frequencies were used in all analyses to calculate national
estimates using discharge weight, or "DISCWT."
Ethics approval statement.

Since the study uses previously gathered deidentified data maintained in
NIS, the study was excused from the institutional review board approval. All of the methodologies followed the
appropriate ethical requirements for handling data.

Informed consent statement. Since this study involves an administrative database that does not contain
any personal information that may be connected to an individual participant, informed consent was not essential.

Results

Characteristics of the cohort. Between 2005 and 2016, 443,222,223 weighted hospitalizations were docu-

mented, with 482,525 of them due to RT complications. Median age of the patients was 66.4 (interquartile range
[IQR, 56.0–76.0]) years. More than half of the patients were ≥ 65 years old. The male-to-female distribution was
relatively equal (52.8 vs. 47.2%). Majority of these patients were white (70.5%, 95% CI 69.1–71.2%)), followed
by blacks (9.8%, 95% CI 8.1–10.7%) and Hispanics (5.8%, 95% CI 4.3–6.5%) (Supplemental Table 2). Almost
two-thirds of patients were admitted to hospitals with large bed size (65.3%, 95% CI 64.3–66.2%) and urban
teaching hospitals (57.9%, 95% CI 56.1–58.7%). The bulk of patients were admitted in the South (37.0%, 95%
CI 35.7–38.2%), according to the region-wise distribution. The in-hospital mortality rate due to complications
of RT was 3.6% (95% CI 2.4–4.6%). The average annual percentage change (AAPC) in hospitalization rates for
radiation complications was 1.1% during the study period, compared to -0.5% for general hospitalizations.
We also analyzed radiotherapy complications by cancer type. Lung (20.8%, 95% CI 19.1–21.6%), prostate
(17.4%, 95% CI 16.8–18.1%), and head and neck (12.0%, 95% CI 10.8–12.7%) cancers were the most common
cancers leading to hospitalization. Among solid tumors, the most common complications were radiation cystitis
(5.0%, 95% CI 4.1–5.6%)), intestinal obstruction (without hernia) (4.2%, 95% CI 3.6–5.1%)), and radiationinduced gastroenteritis and colitis (3.8%, 95% CI 3.1–4.4%), and among hematologic malignancies, the most
common complications were intestinal obstruction (without hernia) (5.5%, 95% CI 4.8–6.7%), radiation-induced
lung injury (5.1%, 95% CI 4.6–6.6%), and esophagitis (2.5%, 95% CI 1.8–3.2%). Figure 1 demonstrates the most
common complications for the ten most common cancer types. Intestinal obstruction (without hernia) was
among the top three complications for bladder, cervix, colon, rectum, anus, and uterine cancers as well as for
non-Hodgkin lymphoma. Esophagitis was among the top three complications for breast, head and neck, lung
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Figure 2.  Relative change in number of hospitalizations for radiation cystitis, radiation-induced lung injury,
aspiration pneumonitis, esophagitis, and disorders of rectum and anus, intestinal obstruction, radiation-induced
gastroenteritis and colitis, gastrointestinal tract hemorrhage, stricture and stenosis of esophagus, and mucositis
from 2006 to 2015.

cancers and non-Hodgkin lymphoma. Radiation-induced gastroenteritis and colitis was commonly seen in
cancers of rectum and anus (24.6%, 95% CI 22.2–25.9%), uterus (13.0%, 95% CI 11.1–14.8%), prostate (11.4%,
95% CI 10.2–12.7%) and colon (8.8%, 95% CI 8.1–9.9%). Disorders of rectum and anus was seen in cancers of
prostate (57.8%, 95% CI 56.1–58.9%), rectum and anus (16.8%, 95% CI 15.1–17.1%)), and cervix (8.8%, 95%
CI 8.1–10.3%).

Factors associated with inpatient admission and mortality.

Aspiration pneumonitis (1.4-fold) and
mucositis (1.3-fold) had the highest relative increases among these hospitalizations from 2005 to 2016, while
esophagitis (0.58-fold) and disorders of the rectum and anus were the lowest (0.67-fold) (see Fig. 2). Table 2
depicts the complications associated with RT with respect to the number of hospitalizations, duration of stay
in the hospital, in-hospital mortality, and expenses. The top reasons for hospitalizations were radiation cystitis
(4.8%, 95% CI 4.2–5.3%), radiation-induced gastroenteritis and colitis (3.7%, 95% CI 3.2–4.2%), and esophagitis (3.5%, 95% CI 3.1–3.9%). The length of stay was highest for aspiration pneumonitis (5.9 days, interquartile
range [IQR] 3.3–10.5), intestinal obstruction without hernia (4.8 days, IQR 2.5–9.7), and mucositis (4.8 days,
IQR 2.7–8.1). In-hospital mortality associated with RT were aspiration pneumonitis (9.6%, 95% CI 8.1–10.9%),
radiation-induced lung injury (7.9%, 95% CI 6.1–8.9%), and stricture and stenosis of esophagus (3.4%, 95% CI
2.2–4.7%). Total hospitalization cost for non-RT was $3.2 trillion and for RT was $6.1 billion (0.20% of total
hospitalization cost). The costliest complications were aspiration pneumonitis ($13,859), intestinal obstruction
without hernia ($10,386), and mucositis ($9,947). The median length of stay of patient for hospitalization for RT
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Number of hospitalizations
(%)

Length of stay in days, median
(IQR)
Mortality, %

Charges per hospitalization
in USD

Total charges during study
period in USD

Radiation cystitis

23,161 (4.8%, 95% CI
4.2–5.3%)

3.6 (1.9–6.4)

1.1

8107

180,642,271

Radiation-induced gastroenteritis and colitis

17,853 (3.7%, 95% CI
3.2–4.2%)

4.1 (2.3–7.5)

1.3

8925

151,254,009

Esophagitis

16,888 (3.5%, 95% CI
3.1–3.9%)

4.4 (2.5–7.6)

1.5

8791

130,639,198

Disorders of rectum and anus

16,888 (3.5%, 95% CI
3.1–3.9%)

2.8 (1.6–4.8)

0.57

6675

102,610,160

Intestinal obstruction without
hernia

16,888 (3.5%, 95% CI
3.1–3.9%)

4.8 (2.5–9.7)

1.4

10,386

191,125,253

Radiation-induced lung injury

10,133 (2.1%, 95% CI
1.8–2.6%)

4.3 (2.4–7.4)

7.9

9651

100,383,570

Gastrointestinal tract hemorrhage

9,658 (2.0%, 95% CI 1.7–2.5%)

2.9 (1.6–5.0)

2.9

7608

68,492,085

Aspiration pneumonitis

6,273 (1.3%, 95% CI 0.7–2.0%)

5.9 (3.3–10.5)

9.6

13,859

77,942,045

Stricture and stenosis of
esophagus

4,735 (0.98%, 95% CI
0.77–1.25%)

4.0 (2.0–7.2)

3.4

9022

43,007,538

Mucositis

4,593 (0.95%, 95% CI
0.76–1.24%)

4.8 (2.7–8.1)

1.7

9947

36,977,567

Diagnosis

Table 2.  Number of hospitalizations, hospital length of stay, in-hospital mortality, and charges for top 10
complications of radiotherapy, 2006–2015.

complications was 4.1 (IQR, 2.2–7.5) days and the median charge per patient was $10,097 (IQR, 5755–18,891)
and the total cost during the study period was $4,9 billion.

Discussion

To our knowledge, this is the first study to use a nationally representative dataset to report hospitalizations for
RT complications. There was an overall decrease in hospitalizations between 2005 and 2016, but hospitalizations
related to complications from RT remained stable over the same time period. A vast majority of these hospitalizations occurred in adults > 60 years of age. In terms of insurance providers and hospital locations associated with
admission, Medicare and urban teaching centers were dominant. The complications associated with the highest
frequency of hospitalization were radiation cystitis, radiation-induced gastroenteritis and colitis, and esophagitis.
The steady rate of hospitalizations for complications of RT, in spite of an overall increase in the number of
patients receiving RT, is likely explained by the overall decrease in adverse events associated with RT over time
because of technical improvements and better management of toxicities in the outpatient setting. Factors such
as improved image guidance during treatment, advanced treatment planning systems and highly conformal and
accurate delivery techniques of radiotherapy such as intensity-modulated radiation therapy (IMRT), imageguided radiation therapy (IGRT), volumetric-modulated arc therapy (VMAT), stereotactic radiotherapy and
particle therapy (proton beam therapy) have been increasingly adopted in the last few years, and have reduced
the dose delivered to normal structures thereby decreasing the intensity of radiation associated side e ffects17.
In this analysis, we noted that the most patients were admitted to large urban teaching hospitals. One possible explanation for this could be the fact that RT facility involves high investment and is usually only available
at larger hospitals, and patients are prone to seeking care at hospitals where they received their RT18. By 2030,
it is projected that 74.1 million (20.6%) Americans will be 65 years or older, and cancer incidence is expected
to increase by 67% between 2010 and 203019. A significant proportion of these patients will receive RT as part
of their treatment20. In our study, we discovered that more than half of the patients who required hospitalization after RT were 65 years and above. Understanding the unique differences that older cancer patients have as
compared to their younger counterparts, both in terms of tumor biology, overall health and functional status
is critical in approaching the management in this patient p
 opulation21, 22. The treating physicians may find it
beneficial to have a working understanding of the available methods for completing a geriatric assessment that
may affect treatment outcomes in older adults in order to provide comprehensive care23.
Radiation therapy is a localized treatment, therefore the complications that may arise are limited to the
organs that are in close proximity to the t umor24. In our study, esophagitis was common among lung and breast
cancers since esophagus is the one of the organs at risk (OAR) in these tumors. Symptoms such as throat pain,
dysphagia, and the feeling that food is stuck in the chest normally appear 2 to 3 weeks after treatment25. The more
the esophagus is included in the radiation field (the region of the body receiving radiation), the higher the risk
of esophagitis. Furthermore, with the introduction of hypofractionation, the patient is more likely to develop
esophagitis26. Similarly, intestinal obstruction was also found to be common among cancers of the bladder, cervix,
colon, rectum, and uterus, owing to the close proximity of the bowels, which serve as the OAR for these tumors.
This condition develops as a result of intestine discomfort following radiation therapy and can be alleviated by
reducing the bowel radiation d
 ose27.
In our study, aspiration pneumonitis, intestinal obstruction without a hernia, and mucositis were all linked
to a longer duration of stay and higher mortality rates in patients undergoing radiotherapy. Given that RT disrupts mucosal barriers, resulting in mucosal alterations and muscle fibrosis, this is understandable. Aspiration
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pneumonitis is caused by a variety of factors, including acute and chronic radiation-induced mucosal changes,
muscle fibrosis, and xerostomia. These factors often result in swallowing difficulties, increasing the risk of aspiration and aspiration pneumonia, as well as the duration of stay in the hospital28–30. Similarly, Berger et al. looked at
the burden of oral mucositis across 65 studies, showed 30% patients required hospitalization due to mucositis31.
We also found that managing the complications of RT from these hospitalizations involved significant expenditures over a 10-year time period—$4.9 billion—leading to an annual estimated health-care burden of $408
million. This poses an enormous burden on healthcare resources. Surprisingly, there are very few studies that
report the cost associated with treating the complications of RT at the national level32. The high hospitalization
rate identified in our study could be used to identify patients whose treatment could be managed in an outpatient
setting. Considering these findings, future studies should focus on estimating the cost associated with these
complications across different healthcare settings, as well as different RT technology platforms, such as 2D, 3D,
IMRT, proton, brachytherapy, etc. A better understanding of variables that predispose patients to toxicities leading to hospitalization could result in prospective interventional approaches. Recommendations for screening
patients at high risk of complications in the outpatient setting and development of standardized management
plans may have real world potential benefits to improve care and reduce hospitalizations.

Limitations

E-codes were utilized to identify patients who had RT-related complications resulting in hospitalization. As NIS
is an administrative database, E-code documentation which is not an obligatory requirement for reimbursement
could result in underestimation of the actual hospitalization burden related to RT complications. Furthermore,
the NIS does not contain data on tumor staging, concomitant medications, or the type and dose of RT administered, making it difficult to perform more sophisticated analysis. Furthermore, because NIS removes all personal identifiers for anonymity, successive readmissions of the same patient would be viewed as separate new
admissions, leading to some overestimation. Despite these drawbacks, we chose NIS since other data sources for
constructing a comprehensive picture of this subject are even more limited and less helpful in terms of national
estimates. NIS is the largest all payer in-patient national database in the United States and its extensive reach
and enormous size regarding data capture makes it more nationally relevant in comparison to other sources.

Conclusions

RT-related hospitalizations are a small percentage of all hospitalizations. During 2005–2016, hospitalization rates
for complications of RT remained almost same and did not show significant reductions; as a rough estimate,
one in every thousand admissions to US hospitals occurs because of a RT-related complication, and this rate has
remained unaltered between 2005 and 2016. The most common RT complication that required hospitalization
were radiation cystitis, radiation-induced gastroenteritis and colitis, and esophagitis. When extrapolated to the
national level for all admissions, the overall financial burden of managing RT related complications from these
hospitalizations over a 10-year time period was $4.9 billion, leading to an annual estimated health-care burden
of $408 million. Improved outpatient and emergency-room strategies for detecting and managing these complications could dramatically reduce the need for these hospitalizations. Identifying patients at greatest risk could
also be useful as they could potentially be treated with more sophisticated techniques that reduce radiation dose
to critical organs-at-risk, thereby likely diminishing toxicities and hospitalizations.

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable
request.
Received: 10 January 2022; Accepted: 28 February 2022

References

1. Cancer Statistics, https://www.cancer.gov/about-cancer/understanding/statistics.
2. Cheng, M., Jolly, S., Quarshie, W. O., Kapadia, N. & Vigneau, F. D. Modern radiation further improves survival in non-small cell
lung cancer: An analysis of 288,670 patients. J. Cancer 10, 168 (2019).
3. Palumbo, M. O. et al. Systemic cancer therapy: Achievements and challenges that lie ahead. Front. Pharmacol. 4, 57 (2013).
4. Halpern, M. T. & Yabroff, K. R. Prevalence of outpatient cancer treatment in the United States: Estimates from the Medical Panel
Expenditures Survey (MEPS). Cancer Investig. 26, 647–651 (2008).
5. Du, X. L., Osborne, C. & Goodwin, J. S. Population-based assessment of hospitalizations for toxicity from chemotherapy in older
women with breast cancer. J. Clin. Oncol. 20, 4636 (2002).
6. Waddle, M. R. et al. Unanticipated hospital admissions during or soon after radiation therapy: Incidence and predictive factors.
Pract. Radiat. Oncol. 5, e245–e253 (2015).
7. Hassett, M. J. et al. Chemotherapy-related hospitalization among community cancer center patients. Oncologist 16, 378–387 (2011).
8. Brooks, G. A. et al. A clinical prediction model to assess risk for chemotherapy-related hospitalization in patients initiating palliative chemotherapy. JAMA Oncol. 1, 441–447 (2015).
9. Du, X. L. et al. Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for
chemotherapy-related toxicity. Cancer Interdiscip. Int. J. Am. Cancer Soc. 104, 913–924 (2005).
10. Ling, D. C. et al. Incidence of hospitalization in patients with head and neck cancer treated with intensity-modulated radiation
therapy. Head Neck 37, 1750–1755 (2015).
11. Gangopadhyay, A., Das, J., Nath, P., Maji, T. & Biswas, J. Incidence of hospitalization in patients receiving short course palliative
cranial radiotherapy on outpatient basis in a limited resource setting—Experience from a regional cancer center in India. Rep.
Pract. Oncol. Radiother. 19, 428–432 (2014).
12. Pyenson, B. S., F. K. Cancer patients receiving chemotherapy: opportunities for better management. (Milliman Inc.) http://us.milli
man.com/uploadedFiles/insight/research/health-rr/cancer-patients-receiving-chemotherapy.pdf.

Scientific Reports |
Vol:.(1234567890)

(2022) 12:4371 |

https://doi.org/10.1038/s41598-022-08491-8

6

www.nature.com/scientificreports/
13. Overview of the National (Nationwide) Inpatient Sample (NIS), https://www.hcup-us.ahrq.gov/nisoverview.jsp.
14. Jairam, V. et al. Treatment-related complications of systemic therapy and radiotherapy. JAMA Oncol. 5(7), 1028–1035 (2019).
15. Khera, R. & Krumholz, H. M. With great power comes great responsibility: Big data research from the National Inpatient Sample.
Circulation Cardiovasc. Qual. Outcomes 10, e003846 (2017).
16. Houchens, R. L, Ross, D. N., Elixhauser, A. & Jiang, J. Nationwide Inpatient Sample Redesign Final Report (2014). HCUP NIS Related
Reports ONLINE. April 4 2014. U.S. Agency for Healthcare Research and Quality. Available: http://www.hcupus.ahrq.gov/db/
nation/nis/nisrelatedreports.jsp.
17. Citrin, D. E. Recent developments in radiotherapy. N. Engl. J. Med. 377, 1065–1075 (2017).
18. McAlearney, A. S., Wellner, J. & Bickell, N. A. Improving breast cancer care measurement and reporting in a complex, urban
hospital setting. J. Healthc. Manag. Am. Coll. Healthc. Executives 58, 205 (2013).
19. Smith, B. D., Smith, G. L., Hurria, A., Hortobagyi, G. N. & Buchholz, T. A. Future of cancer incidence in the United States: Burdens
upon an aging, changing nation. J. Clin. Oncol. 27, 2758–2765 (2009).
20. Smith, B. D. et al. The future of radiation oncology in the United States from 2010 to 2020: Will supply keep pace with demand?.
J. Clin. Oncol. 28, 5160–5165 (2010).
21. Anstey, K. J., Lord, S. R. & Smith, G. A. Measuring human functional age: A review of empirical findings. Exp. Aging Res. 22,
245–266 (1996).
22. Halter, J. B. et al. Hazzard’s Geriatric Medicine and Gerontology (McGraw-Hill Education, 2017).
23. Jiang, S. & Li, P. Current development in elderly comprehensive assessment and research methods. BioMed Res. Int. 2016, 3528248
(2016). https://doi.org/10.1155/2016/3528248
24. Abshire, D. & Lang, M. K. Seminars in oncology nursing. 151–157 (Elsevier).
25. Bradley, J. & Movsas, B. Seminars in Radiation Oncology. 280–286 (Elsevier).
26. Harder, E. M., Chen, Z. J., Park, H. S., Mancini, B. R. & Decker, R. H. Dose-volume predictors of esophagitis after thoracic stereotactic body radiation therapy. Am. J. Clin. Oncol. 40, 477–482 (2017).
27. Kuku, S., Fragkos, C., McCormack, M. & Forbes, A. Radiation-induced bowel injury: The impact of radiotherapy on survivorship
after treatment for gynaecological cancers. Br. J. Cancer 109, 1504–1512 (2013).
28. Akinosoglou, K., Karkoulias, K. & Marangos, M. Infectious complications in patients with lung cancer. Eur. Rev. Med. Pharmacol.
Sci. 17, 8–18 (2013).
29. Rabello, L. S. et al. Clinical outcomes and microbiological characteristics of severe pneumonia in cancer patients: A prospective
cohort study. PLoS ONE 10, e0120544 (2015).
30. Wong, J. L. & Evans, S. E. Bacterial pneumonia in patients with cancer: Novel risk factors and management. Clin. Chest Med. 38,
263–277 (2017).
31. Berger, K. et al. Burden of oral mucositis: A systematic review and implications for future research. Oncol. Res. Treat. 41, 399–405
(2018).
32. Wong, W. et al. Assessment of costs associated with adverse events in patients with cancer. PLoS ONE 13, e0196007 (2018).

Author contributions

Conception and design: R.T., M.R., V.R., R.K. Analysis: M.R., A.S., E.V. Critical review of manuscript: R.T., V.R.,
M.R., A.S., P.G., E.V., M.D.H., M.C., M.S.A., M.P.M., R.K. All authors have read and approved the final version
of the manuscript.

Competing interests

R. Tonse, M. Rubens, V. Ramamoorthy, A. Saxena, E. Veledar, P. McGranaghan: None. M. Hall: Honorarium
from Accuray, Inc. Proton Collaborative Group Executive Committee Institutional Representative and Voting
Member, Miami Cancer Institute (unpaid). Grant Funding: Live Like Bella Pediatric Cancer Research Initiative,
Florida Department of Health Grant 8LA04. M. Chuong: Honorarium from Accuray, Inc., ViewRay Inc., Sirtex
Inc. Advisory board for ViewRay, Inc. Research funding from ViewRay, Inc., Novocure, Inc., AstraZeneca, Inc.
M. S. Ahluwalia: Receipt of grants/research supports: Astrazeneca, BMS, Bayer, Incyte, Pharmacyclics, Novocure,
Mimivax, Merck. Receipt of honoraria or consultation fees: Bayer, Novocure, Kiyatec, Insightec, GSK, Nuvation,
Cellularity, Apollomics. Stock shareholder: Doctible, Mimivax, Cytodyn. M. P. Mehta: Consulting for Karyopharm, Sapience, Zap, Mevion. Board of Directors: Oncoceutics. R. Kotecha: Honoraria from Accuray Inc., Elekta
AB, Viewray Inc., Novocure Inc., Elsevier Inc. Institutional research funding from Medtronic Inc., Blue Earth
Diagnostics Ltd., Novocure Inc., GT Medical Technologies, Astrazeneca, Exelixis, Viewray Inc.

Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/
10.1038/s41598-022-08491-8.
Correspondence and requests for materials should be addressed to R.K.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2022

Scientific Reports |

(2022) 12:4371 |

https://doi.org/10.1038/s41598-022-08491-8

7
Vol.:(0123456789)

